Lisez cet article à voix haute
Activez le micro et lisez à votre rythme. Les mots s’allument au fil de la lecture, et rien ne vous arrête quand l’un d’eux est mal prononcé.
Votre audio n’est jamais envoyé à MovaReader : c’est votre navigateur qui le reconnaît. Politique de confidentialité
Connectez-vous pour garder cette séance dans votre historique de lecture.
Assessing Off-Target Activity in Preclinical CRISPR Gene Editing
The therapeutic deployment of programmable endonucleases, particularly the CRISPR-Cas9 system derived from Streptococcus pyogenes, has revolutionized translational genetics, yet evaluating genomic precision requires rigorous epistemic caution. While standard assays demonstrate that guide RNAs direct the Cas9 endonuclease to cleave targeted loci adjacent to protospacer adjacent motifs, unintended double-strand breaks can occur at non-target sites displaying partial sequence homology. Preclinical evaluations often rely on cell-based selection assays such as GUIDE-seq or in vitro digestion methods like CIRCLE-seq to detect potential off-target cuts. However, molecular geneticists tend to emphasize that cell-free and immortalized cell-line models do not fully mirror chromatin accessibility within primary human tissues.
The biological consequences of off-target cleavage appear to depend heavily on cellular context and repair pathway dynamics. Non-homologous end